PL EN


Preferences help
enabled [disable] Abstract
Number of results
2016 | 16 | 3 | 125–130
Article title

MMP-2 and MMP-9 as prognostic factors in ischaemic stroke

Content
Title variants
PL
MMP-2 i MMP-9 jako czynniki prognostyczne w udarze niedokrwiennym mózgu
Languages of publication
EN
Abstracts
EN
Objectives: No widely available, adequately sensitive diagnostic test to establish prognosis in stroke patients has been developed thus far. The aim of this study was to analyse changes in plasma levels of MMP-9 and MMP-2 as potential prognostic factors in patients with ischaemic stroke. Methods: The study included 56 patients presenting with the signs of ischaemic stroke for less than 24 hours, and 60 healthy controls without a history of neurological and/or inflammatory disorders. Plasma concentrations of MMP-2 and MMP-9 were determined immunoenzymatically at admission (i.e. within 24 hours of the cerebrovascular episode) and on the 7th day of hospital stay. Results: Median concentrations of MMP-9 in stroke patients were significantly lower than in the controls, both at admission and on the 7th day of hospital stay. No significant changes in the concentration of MMP-2 in ischaemic stroke patients were observed during the course of hospital stay. No significant association was found between both MMP concentrations and neurological status of patients with cerebrovascular episodes. Conclusions: The lack of significant associations between plasma concentrations of MMP-2/MMP-9 and clinical status suggests that these metalloproteinases should not be used as prognostic factors in patients with ischaemic cerebral episodes.
PL
Jak dotąd nie został opracowany szeroko dostępny, wystarczająco czuły test diagnostyczny oceniający rokowanie u pacjentów po udarze niedokrwiennym mózgu. Celem niniejszego badania była analiza zmian stężenia MMP-9 i MMP-2 w osoczu jako potencjalnych czynników prognostycznych u chorych z udarem niedokrwiennym mózgu. Metody: Do badania włączono 56 pacjentów z objawami udaru niedokrwiennego utrzymującymi się nie dłużej niż 24 godziny oraz 60 osób zdrowych, bez historii incydentów neurologicznych i/lub zapalnych. Stężenia MMP-2 i  MMP-9 oznaczono immunoenzymatycznie przy przyjęciu (czyli w ciągu 24 godzin od epizodu mózgowego) oraz 7. dnia hospitalizacji. Wyniki: Mediana stężenia MMP-9 w udarze mózgu była znacznie niższa niż w grupie kontrolnej, zarówno przy przyjęciu, jak i 7. dnia pobytu w szpitalu. Nie zaobserwowano znamiennych statystycznie zmian stężenia MMP-2 u osób z udarem niedokrwiennym mózgu w trakcie pobytu w szpitalu. Nie stwierdzono również istotnego związku między stężeniami obu MMP i stanem neurologicznym pacjentów z epizodami mózgowo-naczyniowymi. Wnioski: Brak istotnych związków pomiędzy stężeniami MMP-2/MMP-9 i obrazem klinicznym sugeruje, że metaloproteinazy nie powinny być stosowane jako czynniki prognostyczne u pacjentów z epizodami udaru niedokrwiennego mózgu.
Discipline
Year
Volume
16
Issue
3
Pages
125–130
Physical description
References
  • Castellanos M, Sobrino T, Millan M et al.: Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke 2007; 38: 1855–1859.
  • Corbin ZA, Rost NS, Lorenzano S et al.: White matter hyperintensity volume correlates with matrix metalloproteinase-2 in acute ischemic stroke. J Stroke Cerebrovasc Dis 2014; 23: 1300–1306.
  • Emsley HC, Tyrrell PJ: Inflammation and infection in clinical stroke. J Cereb Blood Flow Metab 2002; 22: 1399–1419.
  • Hernandez-Guillamon M, Martinez-Saez E, Delgado P et al.: MMP-2/ MMP-9 plasma level and brain expression in cerebral amyloid angiopathy-associated hemorrhagic stroke. Brain Pathol 2012; 22: 133–141.
  • Horstmann S, Kalb P, Koziol J et al.: Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 2003; 34: 2165–2170.
  • Jickling GC, Liu D, Stamova B et al.: Hemorrhagic transformation after ischemic stroke in animals and humans. J Cereb Blood Flow Metab 2014; 34: 185–199.
  • Kelly PJ, Morrow JD, Ning M et al.: Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke: the Biomarker Evaluation for Antioxidant Therapies in Stroke (BEAT-Stroke) study. Stroke 2008; 39: 100–104.
  • Kurzepa J, Kurzepa J, Golab P et al.: The significance of matrix metalloproteinase (MMP)-2 and MMP-9 in the ischemic stroke. Int J Neurosci 2014; 124: 707–716.
  • Kurzepa J, Szczepanska-Szerej A, Stryjecka-Zimmer M et al.: Simvastatin could prevent increase of the serum MMP-9/TIMP-1 ratio in acute ischaemic stroke. Folia Biol (Praha) 2006; 52: 181–183.
  • Lenti M, Falcinelli E, Pompili M et al.: Matrix metalloproteinase-2 of human carotid atherosclerotic plaques promotes platelet activation. Correlation with ischaemic events. Thromb Haemost 2014; 111: 1089–1101.
  • Lo EH, Dalkara T, Moskowitz MA: Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003; 4: 399–415.
  • Lucivero V, Prontera M, Mezzapesa DM et al.: Different roles of matrix metalloproteinases-2 and -9 after human ischaemic stroke. Neurol Sci 2007; 28: 165–170.
  • Mackay J, Mensah GA: Deaths from stroke. In: Mackay J, Mensah GA: The Atlas of Heart Disease and Stroke. 1st ed., World Health Organization, Geneva 2004. Montaner J, Alvarez-Sabin J, Molina C et al.: Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001; 32: 1759–1766.
  • Montaner J, Molina CA, Monasterio J et al.: Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598–603.
  • Ott C, Jacobs K, Haucke E et al.: Role of advanced glycation end products in cellular signaling. Redox Biol 2014; 2: 411–429.
  • Rempe RG, Hartz AM, Bauer B: Matrix metalloproteinases in the brain and blood–brain barrier: versatile breakers and makers. J Cereb Blood Flow Metab 2016; 36: 1481–1507.
  • Romi F, Helgeland G, Gilhus NE: Serum levels of matrix metalloproteinases: Implications in clinical neurology. Eur Neurol 2012; 67: 121–128.
  • Rosell A, Lo EH: Multiphasic roles for matrix metalloproteinases after stroke. Curr Opin Pharmacol 2008; 8: 82–89.
  • Sienkiewicz-Jarosz H, Ryglewicz D: [Biomarkers in stroke]. Udar Mózgu 2007; 9: 67–74.
  • Sotgiu S, Zanda B, Marchetti B et al.: Inflammatory biomarkers in blood of patients with acute brain ischemia. Eur J Neurol 2006; 13: 505–513.
  • Wen D, Du X, Nie SP et al.: Association between matrix metalloproteinase family gene polymorphisms and ischemic stroke: a metaanalysis. Mol Neurobiol 2014; 50: 979–985.
  • Woszczycka-Korczyńska I, Górka D, Matuszek I et al.: [Metalloproteinases activity (MMP-2, MMP-9) in distal stumps of rat sciatic nerves]. Wiad Lek 2005; 58: 411–414.
  • Yong VW, Power C, Forsyth P et al.: Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001; 2: 502–511.
  • Zaremba J, Losy J: Immunologiczne aspekty udaru mózgu. In: Losy J, Selmaj K (eds.): Neuroimmunologia kliniczna. Czelej, Lublin 2007.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-39db6baa-a17d-4405-9679-98ff2b7702f5
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.